RMC-9805 in KRAS G12D-Mutant Solid Tumors

Market
100%75%50%25%0%Apr 20 • YES 85.0%Apr 20
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
4/30/26
Study Completion
4/30/27
Sponsor
Revolution Medicines, Inc.
$RVMD
Type
Phase 1/1b
Trial Status
Recruiting
Trial Size
604
Volume
$1
NCT
NCT06040541
Trial Description
Phase 1/1b, open-label, multicenter study evaluating RMC-9805 alone and in combination with RMC-6236 in adults with advanced KRAS G12D-mutant solid tumors. The primary focus is safety and tolerability, with additional pharmacokinetic and preliminary antitumor activity assessments.